# **Sequenom Tools**

### for Cancer Research

Pre-designed and custom panels for rapid mutation profiling





## **Sequenom Tools**

### for Cancer Research


### **Assay Explorer**™

## An online resource for rapid assay selection

An online tool for finding pre-designed assays for genotyping and somatic mutation experiments

- Search for your favorite assays by mutation, gene, disease, or panel
- Request specific assays of interest or opt for an entire panel
- Take advantage of Assays by Sequenom custom design services to gain access to 10s to 100s of ready-to-go assays

Visit www.sequenom.com/explore



### **Assays by Sequenom**

## A Custom Service Program for all your assay needs

Assays by Sequenom allow you to quickly gain access to any of the assays within Assay Explorer™ or have assays designed to your preferred gene, pathway, or disease of investigation. All assays are designed using Sequenom's Assay Design tools with 2-3 rounds of optimization to provide you with 100% working assays. The assays are then run on the MassARRAY® Analyzer system by one of our scientists to verify effective PCR and primer extension.

Assays by Sequenom provide you with a number of options including:

- The reagents you need to run any OncoCarta™ Panel on your MassARRAY® system
- Custom assay or panels for somatic mutation and SNP markers including design, optimization, & reagents
- DNA sample runs against any OncoCarta™ Panel or custom design

MassARRAY, Assay Exporer, OncoCarta and MelaCarta are for Research Use Only. Not for Use in Diagnostic Procedures.



### OncoCarta<sup>™</sup> Panels

## A comprehensive offering for somatic mutation profiling

Sequenom offers a family of pre-designed research mutation panels to accelerate basic cancer and translational research efforts. The OncoCarta™ Panels comprise a large collection of assays for over 50 oncogenes and tumor suppressors previously identified through GWAS, arrays, and sequencing. All assays and panels have been predesigned and optimized for the MassARRAY® Analyzer System. This affords highly accurate and sensitive mutation detection in a variety of heterogeneous tumor samples. The entire collection of OncoCarta™ research mutation panels can be used for targeted discovery to identify candidate markers for drug discovery and development or basic cancer research studies. Alternatively a more focused selection of mutations can be designed into a custom panel to quickly validate the role of particular genes in specific cellular pathways. Key oncogenes, such as BRAF and EGFR, used as targets in a number of commercially available drugs, and tumor suppressors such as PTEN and p53 present in a large percentage of cancers, are just several within the OncoCarta™ research panel family to take advantage of through Assay Explorer™.

### Use Assay Explorer<sup>™</sup> to search through the OncoCarta<sup>™</sup> Panel family

- OncoCarta™ v1.0 the first research panel for comprehensive oncogene analysis with 225 mutations and 19 genes
- OncoCarta<sup>™</sup> v2.0 an extended research panel for investigation of tyrosine kinase and cell signaling pathways such as CTNNB1 and MAP2K with 152 mutations and 18 genes
- OncoCarta™ v3.0 a research panel with 218
  mutations from 26 oncogenes and a number of tumor
  suppressors including PTEN, p53, and RB1
- MelaCarta™ v1.0 a targeted research panel for melanoma cancer screening with 72 mutations and 20 genes

#### OncoCarta™ Panel v1.0

Gene (# mutations)

ABL1 (14); AKT1 (7); AKT2 (2); BRAF (25); CDK4 (2); EGFR (40); ERBB2 (9); FGFR1 (2); FGFR3 (7); FLT3 (3); HRAS (10); JAK2 (1); KIT (32); KRAS (16); MET (5); NRAS (19); PDGFRA (11); PIK3CA (14); RET (6)

#### OncoCarta™ Panel v2.0

AKT1 (1); BRAF (8); CTTNB1 (18); FBX4 (4); FBXW7 (5); FGFR2 (2); FGFR3 (1); GNAQ (2); KIT (42); KRAS (6); MAP2K1 (6); MAP2K2 (5); NRAS (2); PDGFRA (4); PIK3CA (28); PTPN11 (1); SOS1 (3); P53 (14)

#### OncoCarta™ Panel v3.0

ABL1 (2); AKT1 (1); APC (12); BRAF (19); CDKN2A (7); CSF1R (6); CTTNB1 (28); EGFR (32); ERBB2 (2); FLT3 (3); HRAS (2); JAK3 (3); KIT (3); KRAS (5); MET (6); MLH1 (1); MYC (6); PDGFRA (11); PIK3CA (4); PTEN (14); RB1 (11); RET (13); SRC (1); STK11 (12); P53 (7); VH1 (7)

#### MelaCarta™ Panel v1.0

AKT1 (1); BRAF (19); CDK4 (2); CTNNB1 (5); CXCR4 (1); EPHA 10 (1); EPHB6 (2); ERBB4 (2); GNA11 (2); GNAQ (2); KIT (5); KRAS (9); MEK(2); MET (2); NEK10 (1); NRAS (11); PDGFRA (1); PIK3CA (1); PTK2B (2); ROR2 (1)

### For more information please contact your area Sequenom office.

NORTH AMERICA: 1 877 443 6663 EUROPE: (+49) 40 899676 0 ASIA-PACIFIC: (+61) 7 3845 3691

www.sequenom.com

CHINA: (+86) -10-65614168 sequenom.china@sequenom.com

JAPAN: (+81) 3 6802-5590 sequenom.japan@sequenom.com

### **SEQUENOM**°

For research use only. Not for use in diagnostic procedures. ©2010 Sequenom, Inc. All rights reserved. Sequenom, MassARRAY, iPLEX, MassExtend and SpectroCHIP are registered trademarks of Sequenom, Inc., and MassCLEAVE is a trademark used by Sequenom, Inc. Products and/or processes are covered by one or more claims of United States Patent Nos. 6,569,385; 6,300,076; 6,258,538 and foreign equivalents. Other U.S. and foreign patents pending. #sq186\_AssayExplorer2010\_1116-Web